

United
States
of
America

To Promote the Progress



of Science and Useful Arts

The Director

of the United States Patent and Trademark Office has received an application for a patent for a new and useful invention. The title and description of the invention are enclosed. The requirements of law have been complied with, and it has been determined that a patent on the invention shall be granted under the law.

Therefore, this United States

Patent

grants to the person(s) having title to this patent the right to exclude others from making, using, offering for sale, or selling the invention throughout the United States of America or importing the invention into the United States of America, and if the invention is a process, of the right to exclude others from using, offering for sale or selling throughout the United States of America, products made by that process, for the term set forth in 35 U.S.C. 154(a)(2) or (c)(1), subject to the payment of maintenance fees as provided by 35 U.S.C. 41(h). See the Maintenance Fee Notice on the inside of the cover.

Katherine Kelly Vidal

DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE



US012048713B2

(12) **United States Patent**
Shyam et al.

(10) **Patent No.:** **US 12,048,713 B2**
(45) **Date of Patent:** **Jul. 30, 2024**

(54) **PHARMACEUTICAL COMPOSITION FOR REDUCING PROTEIN BOUND UREMIC TOXINS**

(71) Applicant: **Frimline Private Limited**, Ahmedabad (IN)

(72) Inventors: **Ankit Shyam**, Ahmedabad (IN);
Alpesh Chhunchha, Ahmedabad (IN)

(73) Assignee: **Frimline Private Limited**, Ahmedabad Gujarat (IN)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 212 days.

(21) Appl. No.: **17/435,222**

(22) PCT Filed: **Jan. 25, 2021**

(86) PCT No.: **PCT/IB2021/050538**

§ 371 (c)(1),

(2) Date: **Aug. 31, 2021**

(87) PCT Pub. No.: **WO2021/152441**

PCT Pub. Date: **Aug. 5, 2021**

(65) **Prior Publication Data**

US 2022/0370492 A1 Nov. 24, 2022

(30) **Foreign Application Priority Data**

Jan. 27, 2020 (IN) 202021003641

(51) **Int. Cl.**

A61K 31/733 (2006.01)

A61K 31/202 (2006.01)

A61K 31/205 (2006.01)

A61K 31/718 (2006.01)

A61P 13/12 (2006.01)

(52) **U.S. Cl.**

CPC **A61K 31/733** (2013.01); **A61K 31/202** (2013.01); **A61K 31/205** (2013.01); **A61K 31/718** (2013.01); **A61P 13/12** (2018.01)

(58) **Field of Classification Search**

CPC A61K 31/733; A61K 31/205; A61P 13/12
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2016/0051600 A1 2/2016 Martin Del Campo
2019/0350226 A1 11/2019 Gebresalassie

FOREIGN PATENT DOCUMENTS

CN	1504229 A	6/2004
CN	104740611 A	7/2015
EP	2754446 A1	7/2014
FR	2851425 A1	8/2004
WO	2002056710 A1	7/2002
WO	2005056040 A2	6/2005
WO	2019005422 A1	1/2019

OTHER PUBLICATIONS

The John Hopkins. Patient guide to Diabetes (<https://hopkinsdiabetesinfo.org/what-is-resistant-starch/>; Jun. 7, 2018; Hereafter refereed as John Hopkins).*

Barbara U. Metzler-Zebeli et al.; "Effects of betaine, organic acids and inulin as single feed additives or in combination on bacterial populations in the gastrointestinal tract of weaned pigs"; Archives of Animal Nutrition; vol. 63; No. 6; Dec. 2009, pp. 427-441.

David O. McGregor et al., "Betaine supplementation decreases post-methionine hyperhomocysteinemia in chronic renal failure"; Kidney International; vol. 61; 2002; pp. 1040-1046.

* cited by examiner

Primary Examiner — Pancham Bakshi

(74) *Attorney, Agent, or Firm* — BakerHostetler

(57) **ABSTRACT**

The present invention relates to a composition/formulation for reducing uremic toxins, particularly protein bound uremic toxins in chronic kidney disease (CKD). More particularly, the pharmaceutical composition/formulation comprises a synergistic combination of Inulin and Betaine or their pharmaceutically acceptable salts for reducing protein bound uremic toxins. The present application also provides various compositions/formulations and process of preparing the same.

19 Claims, 2 Drawing Sheets